Stabilized human insulin prevents catheter occlusion during continuous subcutaneous insulin infusion.
Obstruction of infusion sets is a major cause of metabolic deterioration or even ketoacidosis during continuous subcutaneous insulin infusion (CSII). 21 type I, CSII-treated patients were studied in a prospective, randomized cross over design during two periods of three months to assess the effects of Genapol stabilized human insulin (HOE 21 PH H-TRONIN) on obstruction frequency of PVC catheters in comparison with a neutral preparation of biosynthetic human insulin (BHI). In a total observation time of 9.5 patient-years 79 catheter obstructions by precipitated insulin occurred with an incidence of 0.67 episodes per patient-month for BHI and 0.026 for HOE 21 PH. Improvement of metabolic control paralleled the reduction of obstruction frequency by HOE 21 PH. Thus, a stabilized insulin preparation is recommended for use in CSII to reduce the therapeutic risk.
Walter
H M
HM
IIIrd Medical Department, City Hospital Munich-Schwabing and Institute for Diabetes Research, FRG.
Timmler
R
R
Mehnert
H
H
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002408:Catheters, Indwelling; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D004355:Drug Stability; D004868:Equipment Failure; D005260:Female; D006801:Humans; D007328:Insulin / Q000737:chemistry / Q000627:therapeutic use*; D007332:Insulin Infusion Systems; D008297:Male; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use
D001786:Blood Glucose; D007328:Insulin; D011994:Recombinant Proteins